Update on biological therapies for knee injuries: Osteoarthritis

Current Reviews in Musculoskeletal Medicine

Volumn 7, Issue 3, 2014, Pages 263-269

  Pintan, Guilherme Figueiredo ^a   De Oliveira, Adilson Sanches ^a   Lenza, Mario ^a   Antonioli, Eliane ^a   Ferretti, Mario ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Biological therapies; Calcitonin; Hyaluronic acid; Knee injuries; Knee osteoarthritis; Mesenchymal stem cells; Nuclear factor B; Osteoarthritis; Platelet rich plasma; Strontium ranelate; Tanezumab; Viscosupplementation

Indexed keywords

CALCITONIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PLACEBO; SMALL INTERFERING RNA; STRONTIUM RANELATE; TANEZUMAB;

ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL THERAPY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FRAGILITY FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; KNEE OSTEOARTHRITIS; KNEE PAIN; MESENCHYMAL STEM CELL TRANSPLANTATION; NAUSEA; NONHUMAN; OSTEOPOROSIS; PARESTHESIA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SUPPLEMENTATION; SYSTEMIC THERAPY; THERAPY EFFECT; THROMBOCYTE RICH PLASMA; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 84906791598     PISSN: 1935973X     EISSN: 19359748     Source Type: Journal    
DOI: 10.1007/s12178-014-9229-8     Document Type: Review

References (40)

1. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26-35.
2. Neustadt DH. Osteoarthritis. In: Rakel RE, editor. Conn's current therapy. Philadelphia: W.B. Saunders; 2003. p. 1075-9.
3. Neogi T, Zhang Y. Epidemiology of osteoarthritis. Rheum Dis Clin N Am. 2013;39:1-19.
4. Ratzlaff CR, Liang MH. New developments in osteoarthritis: prevention of injury-related knee osteoarthritis: opportunities for the primary and secondary prevention of knee osteoarthritis. Arthritis Res Ther. 2010;12:215.
5. Filardo G, Kon E, Di Martino A, DiMatteo B, Merli ML, Cenacchi A, et al. Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial. BMC Musculoskelet Disord. 2012;13:229. This work suggests that PRP provides clinical improvement in patients with up to 1 year of follow-up. However, the results also show that PRP is not much better than HA and should not be considered first-line treatment for knee OA.
6. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014; In press.
7. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23:471-8.
8. Maldonado M, Nam J. The role of changes in extracellular matrix of cartilage in the presence of inflammation on the pathology of osteoarthritis. Biomed Res Int. 2013;2013:284873.
9. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7:33-42.
10. Heinegård D, Saxne T. The role of the cartilage matrix in osteoarthritis. Nat Rev Rheumatol. 2011;7:50-6.
11. McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al.OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363-88. These are the newest guidelines for knee OA management and serve as a database of questions for doctors and patients.
12. Sánchez M, Fiz N, Azofra J, Usabiaga J, Aduriz Recalde E, et al. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) vs hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy. 2012;28:1070-8. This work shows a good safety profile for PRP compared with HA. Also, PRP was more effective in relieving symptoms of mild to moderate knee OA in the short term.
13. Kon E, Filardo G, Drobnic M, Madry H, Jelic M, van Dijk N, et al. Non-surgical management of early knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2012;20:436-49.
14. Rutjes AW, Jüni P, da Costa BR, Trelle S, Nüesch E, Reichenbach S. Viscosupplementation for osteoarthritis of the knee a systematic review and meta-analysis. Ann Intern Med. 2012;157:180-91.
15. Colen S, van den Bekerom MP, Mulier M, Haverkamp D. Hyaluronic acid in the treatment of knee osteoarthritis a systematic review and meta-analysis with emphasis on the efficacy of different products. BioDrugs. 2012;26:257-68.
16. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem. 1999;274:25085-92.
17. Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid vs corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:1704-11.
18. Bannuru RR, Natov NS, Dasi UR, Schmid CH, McAlindon TE. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis-meta-analysis. Osteoarthr Cartil. 2011;19:611-9.
19. Civinini R, Nistri L, Martini C, Redl B, Ristori G, Innocenti M. Growth factors in the treatment of early osteoarthritis. Clin Cases Miner Bone Metab. 2013;10:26-9.
20. Cerza F, Carnì S, Carcangiu A, Di Vavo I, Schiavilla V, Pecora A, et al. Comparison between hyaluronic acid and platelet-rich plasma, intra-articular infiltration in the treatment of gonarthrosis. Am J Sports Med. 2012;40:2822-7.
21. Patel S, Dhillon MS, Aggarwal S, Marwaha N, Jain A. Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial. Am J Sports Med. 2013;41:356-64.
22. Ahlbäck S. Osteoarthrosis of the knee. A radiographic investigation. Acta Radiol Diagn (Stockholm). 1968;277(Suppl):7-72.
23. Li M, Zhang C, Ai Z, Yuan T, Feng Y, Jia W. Therapeutic effectiveness of intra-knee-articular injection of platelet-rich plasma on knee articular cartilage degeneration. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011;25:1192-6.
24. Lodi D, Iannitti T, Palmieri B. Stem cells in clinical practice: applications and warnings. J Exp Clin Cancer Res. 2011;30:9.
25. Koh YG, Choi YJ, Kwon SK, Kim YS, Yeo JE. Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2013; In press.
26. Singh A, Goel SC, Gupta KK, Kumar M, Arun GR, Patil H, et al. The role of stem cells in osteoarthritis: an experimental study in rabbits. Bone Joint Res. 2014;3:32-7.
27. Orth P, Rey-Rico A, Venkatesan JK, Madry H, Cucchiarini M. Current perspectives in stem cell research for knee cartilage repair. Stem Cells Cloning. 2014;7:1-17.
28. Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. 2002;46:704-13.
29. De Bari C, Dell'accio F. Mesenchymal stem cells in rheumatology: a regenerative approach to joint repair. Clin Sci (Lond). 2007;113:339-48.
30. Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res. 2001;19:117-25.
31. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 2009;60:1006-19.
32. Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521-31.
33. Spierings EL, Fidelholtz J, Wolfram G, Smith MD, Brown MT, West CR. A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013;154:1603-12.
34. Nagashima H, Suzuki M, Araki S, Yamabe T, Muto C, Tanezumab investigators. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthr Cartil. 2011;19:1405-12.
35. Schnitzer TJ, Lane NE, Birbara C, Smith MD, Simpson SL, Brown MT. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthr Cartil. 2011;19:639-46.
36. Brown MT, Murphy FT, Radin DM, Davignon I, Smith MD, West CR. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J Pain. 2012;13:790-8.
37. Mobasheri A. The future of osteoarthritis therapeutics: emerging biological therapy. Curr Rheumatol Rep. 2013;15:385. This article presents an overview of the emerging biological therapies for OA, focusing on new concepts of molecular stimulation of neurogenesis and angiogenesis, tanezumab for knee OA pain, and an update on NF-κB.
38. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-kappaB signaling: multiple angles to target OA. Curr Drug Targets. 2010;11:599-613.
39. Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomized placebo-controlled trial. Ann Rheum Dis. 2013;72:179-86.
40. Reginster JY, Beaudart C, Neuprez A, Bruyère O. Strontium ranelate in the treatment of knee osteoarthritis: new insights and emerging clinical evidence. Ther Adv Musculoskelet Dis. 2013;5:268-76.